Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

TCRX

Tscan Therapeutics Inc

Feb 13 • 04:00PM ET

0.9320

-0.0023 -0.25 %

Healthcare • Biotechnology • USA • NASD

Peers: GILD CRSP ALLO NTLA FATE BLUE EDIT CLLS PGEN ADAP

| Held by: VTI VXF IWC BMED

Index	-	P/E	-	EPS (ttm)	-1.12	Insider Own	18.20%	Shs Outstand	52.47M	Perf Week	-9.51%
Market Cap	52.89M	Forward P/E	-	EPS next Y	-0.90	Insider Trans	1.59%	Shs Float	46.42M	Perf Month	-22.33%
Enterprise Value	-35.94M	PEG	-	EPS next Q	-0.27	Inst Own	53.44%	Short Float	5.53%	Perf Quarter	-21.68%
Income	-142.60M	P/S	6.28	EPS this Y	-5.49%	Inst Trans	-0.50%	Short Ratio	4.08	Perf Half Y	-48.51%
Sales	8.42M	P/B	0.37	EPS next Y	25.56%	ROA	-46.73%	Short Interest	2.57M	Perf YTD	-6.80%
Book/sh	2.54	P/C	0.29	EPS next 5Y	6.48%	ROE	-76.44%	52W High	2.57 -63.74%	Perf Year	-54.31%
Cash/sh	3.25	P/FCF	-	EPS past 3/5Y	35.12% -14.41%	ROIC	-61.27%	52W Low	0.88 5.62%	Perf 3Y	-63.88%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-34.76% -	Gross Margin	66.13%	Volatility	6.59% 7.07%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-4.27	EPS Y/Y TTM	11.06%	Oper. Margin	-1765.01%	ATR (14)	0.07	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	6.44	Sales Y/Y TTM	-10.03%	Profit Margin	-1692.96%	RSI (14)	38.11	Recom	1.57
Dividend Gr. 3/5Y	- -	Current Ratio	6.44	EPS Q/Q	-9.21%	SMA20	-10.45%	Beta	1.05	Target Price	5.75
Payout	-	Debt/Eq	0.66	Sales Q/Q	139.37%	SMA50	-10.77%	Rel Volume	0.84	Prev Close	0.93
Employees	194	LT Debt/Eq	0.62	Earnings	Nov 12 BMO	SMA200	-37.96%	Avg Volume	628.62K	Price	0.93
IPO	Jul 16, 2021	Option/Short	No / Yes	EPS/Sales Surpr.	16.24% 27.14%	Trades		Volume	530,679	Change	-0.25%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-14-25	Downgrade	Morgan Stanley	Overweight → Equal-Weight
May-16-24	Initiated	BTIG Research	Buy	$12
May-13-24	Initiated	Needham	Buy	$11
Jun-22-23	Initiated	Wedbush	Outperform	$8

Feb-12-26 07:40AM	Agios Pharmaceuticals (AGIO) Reports Q4 Loss, Beats Revenue Estimates (Zacks)
Feb-11-26 07:25AM	Sutro Biopharma (STRO) Surges 11.9%: Is This an Indication of Further Gains? (Zacks)
Feb-06-26 08:15AM	Roivant Sciences Ltd. (ROIV) Reports Q3 Loss, Misses Revenue Estimates (Zacks) +13.14%
Dec-19-25 07:55AM	Smart Money Abandons Single-Asset Risk: Why Platforms Now Command 60% of Pharma Pipelines (PR Newswire)
Dec-06-25 05:30PM	TScan Therapeutics Announces Positive Updated Data from the ALLOHA Phase 1 Heme Trial at the 67th American Society of Hematology Annual Meeting and Exposition (GlobeNewswire)
12:20PM	Loading…
Dec-04-25 12:20PM	Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points (PR Newswire) +6.86%
Dec-03-25 04:05PM	TScan Therapeutics to Host Virtual KOL Event to Discuss Clinical Updates from the ALLOHA Phase 1 Trial and Future Market Opportunities (GlobeNewswire) +7.12%
Nov-12-25 08:25AM	TScan Therapeutics, Inc. (TCRX) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
07:00AM	TScan Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-10-25 05:10PM	Arcturus Therapeutics (ARCT) Reports Q3 Loss, Beats Revenue Estimates (Zacks) +11.93%
Nov-06-25 09:15AM	Novavax (NVAX) Reports Q3 Loss, Beats Revenue Estimates (Zacks)
Nov-05-25 08:20AM	Arvinas, Inc. (ARVN) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
07:00AM	TScan Therapeutics to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference (GlobeNewswire)
Nov-03-25 06:30AM	TScan Therapeutics Reaches Agreement with FDA on Pivotal Study Design for TSC-101 and Announces Strategic Prioritization to Advance TSC-101 and Extend Cash Runway into H2 2027 (GlobeNewswire) -36.08%
Oct-30-25 09:15AM	Alnylam Pharmaceuticals (ALNY) Q3 Earnings and Revenues Top Estimates (Zacks)
07:30AM	Loading…
Oct-16-25 07:30AM	2 Overlooked Stocks to Snap Up in 2025 (Barchart) +11.21%
Sep-17-25 07:00AM	TScan Therapeutics Announces Upcoming Oral and Poster Presentations at the American College of Rheumatology Convergence 2025 (GlobeNewswire) -6.98%
Sep-03-25 07:00AM	TScan Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire) +6.86%
Aug-12-25 03:00PM	TScan Therapeutics, Inc. (TCRX) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
07:00AM	TScan Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-07-25 09:15AM	Urogen Pharma (URGN) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
Aug-06-25 05:55PM	Mirum Pharmaceuticals, Inc. (MIRM) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
Aug-04-25 08:25AM	Twist Bioscience (TWST) Reports Q3 Loss, Tops Revenue Estimates (Zacks) +5.56%
May-28-25 07:00AM	TScan Therapeutics Announces Upcoming Presentation at the Jefferies Global Healthcare Conference (GlobeNewswire)
May-23-25 09:10AM	New Data and Deal Flow Signal a Turning Point for Precision-Driven Cancer Biotechs (PR Newswire)
May-06-25 08:20AM	TScan Therapeutics, Inc. (TCRX) Reports Q1 Loss, Tops Revenue Estimates (Zacks) -9.33%
07:00AM	TScan Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Apr-28-25 04:53PM	TScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 28th Annual Meeting (GlobeNewswire)
Mar-31-25 07:00AM	TScan Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-27-25 07:00AM	TScan Therapeutics Appoints Commercial Leader Stephen Camiolo as Senior Vice President, Market Access (GlobeNewswire)
08:25AM	Loading…
Mar-05-25 08:25AM	TScan Therapeutics, Inc. (TCRX) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
07:00AM	TScan Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update (GlobeNewswire)
Feb-27-25 07:00AM	TScan Therapeutics Announces Upcoming Presentation at the TD Cowen 45th Annual Health Care Conference (GlobeNewswire) +5.76%
Feb-18-25 07:00AM	TScan Therapeutics to Participate in the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference (GlobeNewswire)
Jan-10-25 09:35AM	Here's Why TScan Therapeutics (TCRX) is Poised for a Turnaround After Losing -5.63% in 4 Weeks (Zacks)
Dec-26-24 07:00AM	TScan Therapeutics Announces $30 Million Registered Direct Offering at a 37% Premium (GlobeNewswire) +6.87%
Dec-23-24 07:00AM	TScan Therapeutics Refinances Existing Convertible Debt Facility with Term Loan for up to $52.5 Million from Silicon Valley Bank (GlobeNewswire)
Dec-09-24 05:45PM	TScan Therapeutics to Present Updated Data from the Ongoing ALLOHA Phase 1 Heme Trial During Oral Session at the 66th American Society of Hematology Annual Meeting and Exposition (GlobeNewswire) -28.23%
Dec-05-24 08:00AM	TScan Therapeutics Named a Top Place to Work by The Boston Globe for Three Consecutive Years (GlobeNewswire) -5.39%
Dec-02-24 07:00AM	TScan Therapeutics to Host Virtual KOL Event to Discuss Clinical Updates from the ALLOHA Phase 1 Trial and Heme Development Strategy (GlobeNewswire)
Nov-12-24 08:25AM	TScan Therapeutics, Inc. (TCRX) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
07:00AM	TScan Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-07-24 04:43AM	TScan Therapeutics (TCRX) Soars 7.6%: Is Further Upside Left in the Stock? (Zacks)
Nov-05-24 09:15AM	TScan Therapeutics Announces Upcoming Oral Presentation of Data from the ALLOHA Phase 1 Heme Trial at the 66th American Society of Hematology Annual Meeting and Exposition (GlobeNewswire)
Oct-04-24 09:05AM	TScan Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer 39th Annual Meeting (GlobeNewswire)
Aug-29-24 07:00AM	TScan Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-12-24 08:15AM	TScan Therapeutics, Inc. (TCRX) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
07:00AM	TScan Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Jun-14-24 07:00AM	TScan Therapeutics Announces Updates to its Board of Directors (GlobeNewswire) -6.67%
May-30-24 07:00AM	TScan Therapeutics Announces Upcoming Presentation at the Jefferies Global Healthcare Conference (GlobeNewswire)
May-29-24 07:00AM	TScan Therapeutics Receives FDA's Regenerative Medicine Advanced Therapy (RMAT) Designation for its Two Lead TCR-T Therapy Candidates for the Treatment of Heme Malignancies (GlobeNewswire) -6.41%
May-28-24 01:24PM	Biotech Sector Working to Combat Rising Cases of Colorectal Cancer in Young Adults (PR Newswire)
May-13-24 01:53PM	TCRX Stock Earnings: TScan Therapeutics Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace)
08:15AM	TScan Therapeutics, Inc. (TCRX) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
07:09AM	Janney Starts TScan Therapeutics With Buy Rating, $11 Price Target (MT Newswires)
07:00AM	TScan Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
May-09-24 07:00AM	TScan Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating TCR-T Therapy for the Treatment of Solid Tumors (GlobeNewswire)
May-01-24 10:01AM	TScan Therapeutics, Inc. (TCRX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release (Zacks) +11.66%
Apr-24-24 04:05PM	TScan Therapeutics Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Meeting (GlobeNewswire)
11:03AM	TScan Therapeutics Announces Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
Apr-22-24 05:01PM	TScan Therapeutics Announces Upcoming Presentations at the American Society of Gene and Cell Therapy 27th Annual Meeting (GlobeNewswire)
Apr-19-24 10:05AM	TScan Therapeutics Announces Closing of Upsized Public Offering (GlobeNewswire)
Apr-17-24 12:30AM	TScan Therapeutics Announces Pricing of Upsized $150 Million Public Offering (GlobeNewswire) -5.33%
Apr-16-24 04:25PM	TScan Therapeutics Announces Launch of $125 Million Proposed Public Offering (GlobeNewswire) -7.28%
04:01PM	TScan Therapeutics Provides Clinical Pipeline Update and Highlights Near-Term Priorities (GlobeNewswire)
Apr-08-24 08:00AM	TScan Therapeutics Appoints Seasoned Hematology and Oncology Expert Chrystal U. Louis, M.D., M.P.H., as Chief Medical Officer (GlobeNewswire)
Apr-02-24 07:00AM	TScan Therapeutics Announces Upcoming Presentation at the 23rd Annual Needham Virtual Healthcare Conference (GlobeNewswire) -10.11%
Mar-17-24 02:58PM	Low-Priced, High-Potential: 7 Cheap Stocks Under $10 to Try Your Luck With (InvestorPlace)
Mar-07-24 01:44PM	TScan Therapeutics Inc (TCRX) Reports Increased Revenue and Expands Clinical Pipeline (GuruFocus.com)
Mar-06-24 01:51PM	TCRX Stock Earnings: TScan Therapeutics Beats EPS, Beats Revenue for Q4 2023 (InvestorPlace)
08:15AM	TScan Therapeutics, Inc. (TCRX) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
07:00AM	TScan Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update (GlobeNewswire)
Feb-28-24 07:00AM	TScan Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference (GlobeNewswire)
Feb-26-24 07:00AM	TScan Therapeutics Presents Promising Updated Phase 1 Clinical Results on TSC-100 and TSC-101 at the 2024 Tandem Meetings of ASTCT and CIBMTR (GlobeNewswire)
Feb-19-24 05:49AM	TScan Therapeutics, Inc. (TCRX) Stock Jumps 18.1%: Will It Continue to Soar? (Zacks)
Feb-14-24 07:00AM	TScan Therapeutics to Host Virtual KOL Event to Discuss Updated Results from Phase 1 Heme Malignancies Study Presented at the 2024 Tandem Meetings of ASTCT and CIBMTR (GlobeNewswire)
Feb-06-24 07:00AM	TScan Therapeutics Expands Clinical Team with the Appointment of Dawn Pinchasik, M.D., M.S., as Vice President, Clinical Development (GlobeNewswire) +6.67%
Jan-29-24 07:00AM	TScan Therapeutics Appoints Seasoned Industry Executive Jason A. Amello as Chief Financial Officer (GlobeNewswire)
Jan-18-24 07:00AM	TScan Therapeutics Announces Best Abstracts Award and Upcoming Oral Presentation at the 2024 Tandem Meetings of ASTCT and CIBMTR (GlobeNewswire) -9.62%
Jan-04-24 07:00AM	TScan Therapeutics Announces 2024 Clinical Plans and Highlights Recent Progress (GlobeNewswire)
Dec-09-23 12:00PM	TScan Therapeutics Presents Initial Phase 1 Clinical Results on TSC-100 and TSC-101 at the 65th American Society of Hematology Annual Meeting and Exposition (GlobeNewswire)
Dec-07-23 07:00AM	TScan Therapeutics Appoints R. Keith Woods to its Board of Directors, Bringing Expertise in Commercialization and Global Operations (GlobeNewswire)
Dec-06-23 08:50AM	Recent Price Trend in TScan Therapeutics, Inc. (TCRX) is Your Friend, Here's Why (Zacks)
Dec-04-23 04:05PM	TScan Therapeutics to Host Virtual KOL Event to Discuss Results from Ongoing Phase 1 Trial of TSC-100 and TSC-101 Presented at the 65th ASH Annual Meeting and Exposition (GlobeNewswire) -5.56% +10.46%
07:00AM	TScan Therapeutics Expands Manufacturing Leadership with the Appointment of Justin McCue, Ph.D., as Chief Technology Officer (GlobeNewswire)
Dec-01-23 09:55AM	Does TScan Therapeutics, Inc. (TCRX) Have the Potential to Rally 62.33% as Wall Street Analysts Expect? (Zacks)
Nov-30-23 07:00AM	TScan Therapeutics Named Top Place to Work by The Boston Globe for Two Consecutive Years (GlobeNewswire) +12.98%
Nov-27-23 12:00PM	TScan Therapeutics, Inc. (TCRX) is a Great Momentum Stock: Should You Buy? (Zacks)
Nov-20-23 08:50AM	TScan Therapeutics, Inc. (TCRX) Is a Great Choice for 'Trend' Investors, Here's Why (Zacks) -13.83%
Nov-15-23 12:00PM	What Makes TScan Therapeutics, Inc. (TCRX) a New Buy Stock (Zacks)
09:55AM	Wall Street Analysts Predict a 125% Upside in TScan Therapeutics, Inc. (TCRX): Here's What You Should Know (Zacks)
Nov-09-23 08:25AM	TScan Therapeutics Inc (TCRX) Reports Q3 2023 Financial Results and Corporate Updates (GuruFocus.com)
07:00AM	TScan Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-06-23 07:00AM	TScan Therapeutics Presents Phase 1 Trial Design for Solid Tumor Program at the Society for Immunotherapy of Cancer 38th Annual Meeting (GlobeNewswire) +11.03%
Nov-02-23 09:05AM	TScan Therapeutics Announces Upcoming Presentation at the 65th American Society of Hematology Annual Meeting and Exposition (GlobeNewswire) +7.73%
Oct-12-23 12:00PM	TScan Therapeutics, Inc. (TCRX) Upgraded to Strong Buy: Here's Why (Zacks)
Sep-27-23 09:06AM	TScan Therapeutics Announces Upcoming Presentations at the 38th Society for Immunotherapy of Cancer Annual Meeting (GlobeNewswire)
Sep-12-23 08:00AM	Sensorium Therapeutics Appoints Veteran Life Sciences Executive Mr. David Southwell to its Board of Directors (GlobeNewswire)
Sep-05-23 07:00AM	TScan Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-29-23 07:00AM	TScan Therapeutics Announces FDA Clearance of Investigational New Drug Application for TSC-203-A0201 Targeting PRAME (GlobeNewswire) +10.96%

TScan Therapeutics, Inc. discovers and develops transformative T cell therapies (TCR-T) to treat liquid cancers, solid tumors and other serious diseases. Its platform identifies previously uncharacterized, clinically-derived shared T cell antigens and all off-target TCR interactions, to enable the development of efficacious TCR-Ts. The company was founded by Christoph H. Westphal, Stephen Elledge, Lea Hachigian, and Tomasz Kula in 2018 and is headquartered in Boston, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Lynx1 Capital Management LP	10% Owner	Dec 19 '25	Buy	0.90	80,069	71,974	7,937,416	Dec 23 06:17 PM
Lynx1 Capital Management LP	10% Owner	Dec 22 '25	Buy	0.90	75,500	67,950	8,012,916	Dec 23 06:17 PM
Lynx1 Capital Management LP	10% Owner	Dec 23 '25	Buy	0.90	6,232	5,602	8,019,148	Dec 23 06:17 PM
Lynx1 Capital Management LP	10% Owner	May 19 '25	Buy	1.20	1,388,794	1,666,553	6,746,141	May 21 04:49 PM
Lynx1 Capital Management LP	10% Owner	May 20 '25	Buy	1.20	1,200,000	1,440,000	7,946,141	May 21 04:49 PM

Open in Screener

CGEM

Cullinan Therapeutics Inc

Feb 13 • 04:00PM ET

11.59

-0.10 -0.86 %

Healthcare • Biotechnology • USA • NASD

CGEM Cullinan Therapeutics Inc daily Stock Chart

Peers: GILD INCY JAZZ NVAX KURA EXEL BPMC KPTI ESPR ONCY

| Held by: VTI IWM XBI VXF IWN IBB SCHA VTWO DFAS DFAC

Index	RUT	P/E	-	EPS (ttm)	-3.68	Insider Own	33.83%	Shs Outstand	59.08M	Perf Week	-5.23%
Market Cap	684.69M	Forward P/E	-	EPS next Y	-3.11	Insider Trans	10.14%	Shs Float	39.09M	Perf Month	6.62%
Enterprise Value	353.28M	PEG	-	EPS next Q	-0.80	Inst Own	76.27%	Short Float	20.41%	Perf Quarter	38.80%
Income	-216.81M	P/S	-	EPS this Y	-27.49%	Inst Trans	1.15%	Short Ratio	7.89	Perf Half Y	52.90%
Sales	0.00M	P/B	1.52	EPS next Y	12.15%	ROA	-38.12%	Short Interest	7.98M	Perf YTD	11.98%
Book/sh	7.64	P/C	2.06	EPS next 5Y	0.67%	ROE	-40.18%	52W High	13.43 -13.70%	Perf Year	20.86%
Cash/sh	5.63	P/FCF	-	EPS past 3/5Y	-28.11% -45.66%	ROIC	-48.03%	52W Low	5.68 104.05%	Perf 3Y	4.89%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	7.34% 7.04%	Perf 5Y	-71.02%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-27.86%	Oper. Margin	-	ATR (14)	0.84	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	10.45	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	49.23	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	10.45	EPS Q/Q	-23.21%	SMA20	-3.37%	Beta	-0.09	Target Price	30.36
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	3.31%	Rel Volume	0.83	Prev Close	11.69
Employees	111	LT Debt/Eq	0.00	Earnings	Nov 06 BMO	SMA200	33.64%	Avg Volume	1.01M	Price	11.59
IPO	Jan 08, 2021	Option/Short	Yes / Yes	EPS/Sales Surpr.	18.69% -	Trades		Volume	840,566	Change	-0.86%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-02-26	Initiated	Guggenheim	Buy	$30
Aug-21-25	Resumed	H.C. Wainwright	Buy	$24
Jun-11-25	Resumed	Stifel	Buy	$22
Oct-24-24	Initiated	UBS	Buy	$30
May-01-24	Initiated	Stifel	Buy	$40
Apr-15-24	Initiated	William Blair	Outperform
Feb-15-24	Initiated	Wedbush	Outperform	$30
Jun-15-23	Initiated	TD Cowen	Outperform
Nov-21-22	Initiated	BTIG Research	Buy	$20
Apr-27-21	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$40
Feb-02-21	Initiated	SVB Leerink	Outperform	$52
Feb-02-21	Initiated	Morgan Stanley	Equal-Weight	$38
Feb-02-21	Initiated	Evercore ISI	Outperform	$55
Feb-01-21	Initiated	H.C. Wainwright	Buy	$47

Show Previous Ratings

Feb-13-26 02:09AM	Cullinan Therapeutics Tees Up Catalyst-Heavy 2026 With Q2 CLN-978 Data and AML Fast Track Momentum (MarketBeat)
Feb-05-26 07:00AM	Cullinan Therapeutics to Participate in Fireside Chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 (GlobeNewswire)
Jan-28-26 09:40AM	Are Medical Stocks Lagging AIM ImmunoTech (AIM) This Year? (Zacks)
Jan-23-26 08:55AM	Here's What Could Help Cullinan Therapeutics (CGEM) Maintain Its Recent Price Strength (Zacks)
Jan-09-26 07:15AM	Cullinan Therapeutics provides corporate update, anticipated 2026 milestones (TipRanks)
07:00AM	Loading…
Jan-08-26 07:00AM	Cullinan Therapeutics Provides Corporate Update and Highlights Anticipated 2026 Milestones (GlobeNewswire)
Dec-15-25 11:10PM	Cullinan Therapeutics (CGEM) Jumps on Promising Phase 1 Data for CLN-049 in AML, Showing Strong Response Rates (Insider Monkey) -9.23% -5.55%
Dec-08-25 10:31AM	Cullinan Therapeutics Showcases Compelling Clinical Data in AML for CLN-049, Novel FLT3xCD3 T Cell Engager, in Oral Presentation at the 67th ASH Meeting (GlobeNewswire) +17.47%
Dec-01-25 07:00AM	Cullinan Therapeutics Receives FDA Fast Track Designation for CLN-049, a Novel FLT3xCD3 T Cell Engager, in Relapsed/Refractory Acute Myeloid Leukemia (GlobeNewswire) -5.45%
Nov-10-25 07:00AM	Cullinan Therapeutics to Participate in Upcoming Investor Conferences and Host Analyst and Investor Event at 2025 ASH Annual Meeting (GlobeNewswire)
Nov-06-25 07:38AM	Cullinan Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Cullinan Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results (GlobeNewswire)
Nov-03-25 09:11AM	Cullinan Therapeutics to Showcase New Data Demonstrating Compelling Clinical Activity for CLN-049, a Novel FLT3xCD3 T Cell Engager, in AML Patients in an Oral Presentation at the 67th ASH Annual Meeting (GlobeNewswire) -9.82%
Oct-25-25 11:01AM	Cullinan Therapeutics Shares Additional Preclinical B Cell Depletion Data for CLN-978, Supporting Clinical Development Across Multiple Autoimmune Diseases, at ACR Convergence 2025 (GlobeNewswire)
Sep-23-25 10:23AM	BDTX vs. Cullinan Therapeutic: Which EGFR Challenger Is the Better Buy? (Zacks)
07:00AM	Loading…
Sep-12-25 07:00AM	Cullinan Therapeutics to Participate in Fireside Chat at the Stifel 2025 Virtual Immunology and Inflammation Forum (GlobeNewswire)
Aug-21-25 04:05PM	Cullinan Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire) +6.78%
Aug-07-25 07:15AM	Cullinan Therapeutics: Q2 Earnings Snapshot (Associated Press Finance) -10.79%
07:00AM	Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results (GlobeNewswire)
Jul-31-25 11:40PM	Cullinan Therapeutics to Present Updated Zipalertinib Data at IASLC 2025 World Conference on Lung Cancer (Insider Monkey)
Jul-22-25 07:00AM	Taiho Oncology and Cullinan Therapeutics Announce Acceptance of Abstracts for Zipalertinib at the IASLC 2025 World Conference on Lung Cancer (PR Newswire) +7.85%
Jul-14-25 08:30AM	Disc Medicine Appoints Nadim Ahmed to its Board of Directors (GlobeNewswire)
Jun-05-25 07:31AM	Cullinan doubles down on bispecifics for autoimmune disease with Genrix deal (BioPharma Dive)
Jun-04-25 04:02PM	Cullinan Therapeutics Licenses Rights to Velinotamig, a Clinical-Stage BCMA-Directed Bispecific T Cell Engager, from Genrix Bio for Development in Autoimmune Diseases (GlobeNewswire)
Jun-01-25 08:21AM	Taiho Oncology and Cullinan Therapeutics Announce Pivotal REZILIENT1 Phase 1/2 Data Published in the Journal of Clinical Oncology (PR Newswire)
May-29-25 07:00AM	Cullinan Therapeutics to Host Analyst and Investor Event at 2025 ASCO Annual Meeting and Participate in Jefferies 2025 Global Healthcare Conference (GlobeNewswire) +10.71%
May-22-25 05:15PM	Cullinan Therapeutics, Taiho Pharmaceutical, and Taiho Oncology to Present Positive Results from Pivotal Phase 2b REZILIENT1 Trial of Zipalertinib at ASCO 2025 (GlobeNewswire)
May-08-25 07:00AM	Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results (GlobeNewswire)
May-01-25 09:55AM	Wall Street Analysts Predict a 292.51% Upside in Cullinan Therapeutics (CGEM): Here's What You Should Know (Zacks)
Apr-29-25 07:00AM	Cullinan Therapeutics to Initiate Study of CLN-978, a Bispecific CD19 T Cell Engager Administered Subcutaneously, in Patients with Sj gren's Disease in the United States (GlobeNewswire)
10:14AM	Loading…
Apr-23-25 10:14AM	Cullinan Therapeutics to Present Results from REZILIENT1, a Phase 1/2 Trial of Zipalertinib in Patients with Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations Who Have Received Prior Therapy, at ASCO 2025 (GlobeNewswire)
Apr-16-25 07:00AM	Cullinan Therapeutics Receives Approval from European Medicines Agency to Initiate Phase 1 Trial of CLN-978, a Bispecific CD19 T Cell Engager Administered Subcutaneously, in Patients with Rheumatoid Arthritis (GlobeNewswire)
Apr-08-25 10:42AM	Cullinan Therapeutics: Attractive Pipeline Progress, But We Will Wait For Complete Phase 2b Data (Seeking Alpha)
Feb-27-25 07:00AM	Cullinan Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire)
Feb-24-25 07:00AM	Cullinan Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Jan-30-25 07:00AM	Cullinan Therapeutics to Participate in Fireside Chat at the Guggenheim Securities SMID Cap Biotech Conference (GlobeNewswire)
Jan-28-25 07:00PM	Taiho Pharmaceutical, Taiho Oncology, and Cullinan Therapeutics Announce Primary Endpoint Met in Phase 2b Trial of Zipalertinib in Patients with Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations Who Have Received Prior Therapy (PR Newswire) +7.66%
Nov-14-24 10:01AM	Cullinan Therapeutics Announces Preclinical Data for CLN-978, a CD19-directed T Cell Engager, to be Presented at ACR Convergence 2024 (GlobeNewswire)
Nov-07-24 07:00AM	Cullinan Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results (GlobeNewswire) -5.46%
Nov-05-24 07:00AM	Cullinan Therapeutics to Participate in Fireside Chat at Stifel 2024 Healthcare Conference (GlobeNewswire)
Nov-04-24 07:00AM	Cullinan Therapeutics to Present Preclinical Data for CLN-978, a CD19-directed T Cell Engager, at ACR Convergence 2024 (GlobeNewswire)
Oct-16-24 07:00AM	Cullinan Therapeutics Receives U.S. FDA Clearance of Investigational New Drug Application for CLN-978 Administered Subcutaneously in Patients with Moderate to Severe Systemic Lupus Erythematosus (GlobeNewswire) +8.44%
Sep-17-24 07:00AM	Cullinan Therapeutics Receives Approval to Initiate its Global Phase 1 Clinical Trial of CLN-978 for the Treatment of Systemic Lupus Erythematosus (GlobeNewswire)
Sep-16-24 07:00AM	Cullinan Therapeutics Announces Submission of Investigational New Drug Application to U.S. Food and Drug Administration for CLN-978 to Treat Systemic Lupus Erythematosus (GlobeNewswire) -5.68%
Sep-14-24 04:15AM	Cullinan Therapeutics Presents Positive Updated Data from Module C of Zipalertinib Pivotal Phase 2b Study at ESMO 2024 (GlobeNewswire)
Aug-28-24 08:00AM	Cullinan Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-08-24 07:00AM	Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results (GlobeNewswire)
Jun-03-24 06:26AM	Cullinan Therapeutics announces success for zipalertinib as combo therapy (Clinical Trials Arena)
Jun-01-24 07:00AM	Cullinan Therapeutics Announces Positive Initial Data from Pivotal Phase 2b REZILIENT1 Study of Zipalertinib (GlobeNewswire)
May-24-24 08:00AM	Cullinan Therapeutics to Participate in Fireside Chat at TD Cowen 5th Annual Oncology Innovation Summit (GlobeNewswire) +6.53%
May-23-24 05:04PM	Cullinan Therapeutics to Present First Data for CLN-619, a Novel Anti-MICA/B Antibody, in Combination with a Checkpoint Inhibitor and Updated Monotherapy Data at ASCO 2024 (GlobeNewswire)
May-16-24 12:03PM	HC Wainwright Adjusts Price Target on Cullinan Oncology to $28 From $29, Maintains Buy Rating (MT Newswires) -10.89%
May-15-24 10:54PM	CGEM Stock Earnings: Cullinan Oncology Beats EPS for Q1 2024 (InvestorPlace)
04:05PM	Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results (GlobeNewswire)
May-09-24 03:09AM	Insider Sale at Cullinan Therapeutics Inc (CGEM): Chief Scientific Officer Jennifer Michaelson ... (GuruFocus.com)
May-01-24 07:05AM	Stifel Initiates Cullinan Oncology With Buy Rating, $40 Price Target (MT Newswires)
Apr-29-24 07:00AM	Cullinan Therapeutics Announces Appointment of Mary Kay Fenton as Chief Financial Officer (GlobeNewswire) +7.19%
Apr-24-24 04:29PM	Why Is Cullinan Therapeutics Stock Trading Higher On Wednesday? (Benzinga) +13.32%
10:09AM	Cullinan Therapeutics to Present Clinical Data from Phase 1 Study Evaluating Novel Anti-MICA/B Antibody, CLN-619, as Monotherapy and in Combination with a Checkpoint Inhibitor in Patients with Advanced Solid Tumors at ASCO 2024 (GlobeNewswire)
Apr-16-24 03:32PM	Cullinan Shifts Focus From Oncology To Autoimmune Disorders, Raises $280M Via Equity (Benzinga)
07:00AM	Cullinan Therapeutics Announces Strategic Expansion into Autoimmune Diseases (GlobeNewswire)
06:59AM	Cullinan Therapeutics Announces Oversubscribed $280 million Private Placement (GlobeNewswire)
04:48AM	Cullinan changes name, pivots to autoimmune disease (BioPharma Dive)
Mar-16-24 05:31AM	Cullinan Oncology Inc (CGEM) Reports Fourth Quarter and Full Year 2023 Financial Results (GuruFocus.com)
Mar-14-24 12:53PM	CGEM Stock Earnings: Cullinan Oncology Beats EPS for Q4 2023 (InvestorPlace)
07:00AM	Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire)
Mar-01-24 07:00AM	Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for Novel MICA/B Antibody, CLN-619, for Relapsed/Refractory Multiple Myeloma (GlobeNewswire)
Feb-27-24 08:00AM	Cullinan Oncology to Participate in Upcoming Investor Conferences (GlobeNewswire)
Feb-21-24 09:21AM	13 Best Booming Stocks to Buy Right Now (Insider Monkey)
Feb-02-24 11:01PM	Chief Business Officer Corrine Savill Sells 40,000 Shares of Cullinan Oncology Inc (GuruFocus.com)
Jan-30-24 11:01PM	Chief Business Officer Corrine Savill Sells 40,000 Shares of Cullinan Oncology Inc (GuruFocus.com)
Jan-24-24 07:02PM	Insider Sell: Cullinan Oncology Inc's Chief Business Officer Corrine Savill Sold 40,000 Shares (GuruFocus.com)
Dec-18-23 04:53PM	Cullinan Oncology to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) +10.80%
Dec-14-23 04:30PM	Cullinan Oncology Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-617, a Novel Fusion Protein Uniquely Harnessing Both IL-2 and IL-12 Cytokines (GlobeNewswire)
Nov-08-23 07:00AM	Cullinan Oncology Provides Corporate Update and Reports Third Quarter 2023 Financial Results (GlobeNewswire)
Nov-03-23 12:01PM	Cullinan Oncology to Present Data Demonstrating Progress Across Its Broad Immunotherapy-Pipeline at SITC 2023 (GlobeNewswire) +5.53%
Oct-30-23 08:00AM	Cullinan Oncology to Participate in Upcoming Investor Conferences (GlobeNewswire)
Sep-06-23 08:00AM	Cullinan Oncology to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-10-23 07:00AM	Cullinan Oncology Provides Corporate Update and Reports Second Quarter 2023 Financial Results (GlobeNewswire)
Aug-09-23 07:00AM	Cullinan Oncology Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-978, a Novel CD19xCD3 T cell Engager, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (GlobeNewswire)
Aug-03-23 04:15PM	REZILIENT3 Global First-Line Trial of Zipalertinib Launched in Patients With Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations (PR Newswire)
Jul-31-23 08:00AM	Cullinan Oncology to Participate in Upcoming Investor Conferences (GlobeNewswire)
Jun-09-23 04:07PM	Why Shares of Cullinan Oncology Jumped This Week (Motley Fool)
May-25-23 05:00PM	Cullinan Oncology to Present First Monotherapy Clinical Data for CLN-619, a Novel Anti-MICA/B Antibody, at ASCO 2023 (GlobeNewswire) +5.13%
May-11-23 04:01PM	Cullinan Oncology Provides Corporate Update and Reports First Quarter 2023 Financial Results (GlobeNewswire)
Apr-26-23 10:08AM	Cullinan Oncology to Present First Clinical Data Evaluating Novel Anti-MICA/B Antibody, CLN-619, in Patients with Advanced Solid Tumors at ASCO 2023 (GlobeNewswire)
Apr-20-23 07:00AM	Cullinan Oncology to Participate in Stifels 2023 Targeted Oncology Days (GlobeNewswire)
Mar-29-23 10:13AM	12 Cheap Healthcare Stocks to Buy in 2023 (Insider Monkey)
Mar-27-23 07:00AM	Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for CLN-617, a Novel Fusion Protein Harnessing IL-2 and IL-12 Cytokines (GlobeNewswire)
Mar-14-23 04:35PM	Cullinan Oncology to Present New Preclinical Data for CLN-619 and CLN-617 at the 2023 American Association for Cancer Research Annual Meeting (GlobeNewswire)
Mar-09-23 07:00AM	Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results (GlobeNewswire)
Feb-27-23 08:00AM	Cullinan Oncology to Participate in Cowens 43rd Annual Health Care Conference (GlobeNewswire)
Feb-13-23 07:00PM	Cullinan Oncology Licenses U.S. Rights to the First Clinical-Stage B7H4 x 4-1BB Bispecific Immune Activator from Harbour BioMed (GlobeNewswire)
Feb-02-23 04:01PM	Cullinan Oncology to Participate in the Guggenheim 5th Annual Oncology Conference and the SVB Securities Global Biopharma Conference (GlobeNewswire)
Feb-01-23 04:42PM	Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-24-23 08:00AM	Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for CLN-978, a Novel T-Cell Engager for the Treatment of Relapsed/Refractory B-cell Non-Hodgkin Lymphoma (GlobeNewswire) +5.53%
Jan-23-23 11:07AM	12 Most Undervalued Pharma Stocks To Buy According To Hedge Funds (Insider Monkey)
Jan-03-23 05:13PM	Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-28-22 10:31PM	11 Cheap Value Stocks to Buy According to Seth Klarman (Insider Monkey)
Dec-02-22 05:00PM	Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)

Cullinan Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the developing of oncology and immuno-oncology therapies. Its pipeline includes CLN-978, CLN-619, Zipalertinib CLN-081/TAS6417, CLN-049, and CLN-617. The company was founded by Patrick A. Baeuerle on September 15, 2016 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Michaelson Jennifer	Chief Scientific Officer	Feb 12 '26	Sale	12.03	416	5,004	128,219	Feb 13 05:00 PM
Michaelson Jennifer	Chief Scientific Officer	Jan 22 '26	Sale	12.30	4,000	49,200	128,635	Jan 23 05:00 PM
JENNIFER MICHAELSON	Officer	Jan 22 '26	Proposed Sale	11.60	4,000	46,400		Jan 22 04:33 PM
AHMED NADIM	President and CEO	Dec 23 '25	Sale	10.01	9,922	99,319	420,699	Dec 29 05:00 PM
Michaelson Jennifer	Chief Scientific Officer	Dec 19 '25	Sale	10.01	1,345	13,463	132,635	Dec 22 05:00 PM
SUMER JACQUELYN L	Chief Legal Officer	Dec 18 '25	Sale	9.67	3,480	33,652	135,432	Dec 19 05:00 PM
Jones Jeffrey Alan	Chief Medical Officer	Dec 18 '25	Sale	9.67	4,632	44,791	169,532	Dec 19 05:00 PM
Michaelson Jennifer	Chief Scientific Officer	Dec 18 '25	Sale	9.67	2,898	28,024	133,980	Dec 19 05:00 PM
JENNIFER MICHAELSON	Officer	Dec 19 '25	Proposed Sale	9.98	1,345	13,423		Dec 19 04:23 PM
Michaelson Jennifer	Chief Scientific Officer	Dec 12 '25	Sale	12.38	2,148	26,592	137,873	Dec 16 05:00 PM
Michaelson Jennifer	Chief Scientific Officer	Dec 15 '25	Sale	11.90	995	11,840	136,878	Dec 16 05:00 PM
JENNIFER MICHAELSON	Officer	Dec 15 '25	Proposed Sale	11.92	995	11,860		Dec 15 04:16 PM
Michaelson Jennifer	Chief Scientific Officer	Nov 24 '25	Sale	12.30	4,000	49,200	138,004	Nov 25 05:00 PM
JENNIFER MICHAELSON	Officer	Nov 24 '25	Proposed Sale	9.47	4,000	37,880		Nov 24 04:28 PM
Lynx1 Capital Management LP	10% Owner	Oct 28 '25	Buy	8.40	165,667	1,391,686	8,963,500	Oct 30 05:13 PM
Lynx1 Capital Management LP	10% Owner	Oct 16 '25	Buy	8.86	150,000	1,328,250	8,765,616	Oct 21 07:00 PM
Lynx1 Capital Management LP	10% Owner	Oct 15 '25	Buy	7.94	51,500	409,049	8,615,616	Oct 21 07:00 PM
Lynx1 Capital Management LP	10% Owner	Oct 17 '25	Buy	7.84	32,217	252,565	8,797,833	Oct 21 07:00 PM
Lynx1 Capital Management LP	10% Owner	Oct 14 '25	Buy	7.59	15,032	114,048	8,564,116	Oct 21 07:00 PM
Lynx1 Capital Management LP	10% Owner	Oct 09 '25	Buy	6.70	626,043	4,191,859	8,271,786	Oct 10 06:58 PM
Lynx1 Capital Management LP	10% Owner	Oct 08 '25	Buy	6.46	556,300	3,593,698	7,645,743	Oct 10 06:58 PM
Lynx1 Capital Management LP	10% Owner	Oct 10 '25	Buy	7.36	277,298	2,041,385	8,549,084	Oct 10 06:58 PM
Jones Jeffrey Alan	Chief Medical Officer	Feb 25 '25	Sale	8.53	4,895	41,754	174,164	Feb 27 05:00 PM
AHMED NADIM	President and CEO	Feb 25 '25	Sale	8.53	12,529	106,872	430,621	Feb 27 05:00 PM
Michaelson Jennifer	Chief Scientific Officer	Feb 25 '25	Sale	8.53	3,756	32,039	142,004	Feb 27 05:00 PM
SUMER JACQUELYN L	Chief Legal Officer	Feb 25 '25	Sale	8.53	3,756	32,039	136,895	Feb 27 05:00 PM

Open in Screener

NEUP

Neuphoria Therapeutics Inc

Feb 13 • 04:00PM ET

4.05

-0.02 -0.49 %

Healthcare • Biotechnology • USA • NASD

NEUP Neuphoria Therapeutics Inc daily Stock Chart

Peers: BHVN FATE CORT NKTR ARWR KNSA CRSP AKRO BPMC QURE

| Held by: PSIL VXF

Index	-	P/E	-	EPS (ttm)	-23.89	Insider Own	9.09%	Shs Outstand	-	Perf Week	1.00%
Market Cap	7.61M	Forward P/E	-	EPS next Y	-2.43	Insider Trans	373.98%	Shs Float	1.71M	Perf Month	0.25%
Enterprise Value	-6.00M	PEG	-	EPS next Q	-0.56	Inst Own	78.21%	Short Float	2.16%	Perf Quarter	-17.35%
Income	5.83M	P/S	0.49	EPS this Y	-1669.57%	Inst Trans	33.34%	Short Ratio	0.57	Perf Half Y	-50.00%
Sales	15.66M	P/B	0.76	EPS next Y	40.29%	ROA	-	Short Interest	0.04M	Perf YTD	4.38%
Book/sh	5.31	P/C	0.55	EPS next 5Y	-	ROE	-	52W High	21.40 -81.08%	Perf Year	-11.96%
Cash/sh	7.30	P/FCF	16.20	EPS past 3/5Y	-17.62% -20.01%	ROIC	46.58%	52W Low	3.64 11.11%	Perf 3Y	-91.56%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	334.17% 246.61%	Gross Margin	-	Volatility	2.42% 3.17%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-0.38	EPS Y/Y TTM	-15957.73%	Oper. Margin	-4.93%	ATR (14)	0.15	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	2.72	Sales Y/Y TTM	-	Profit Margin	37.20%	RSI (14)	48.44	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	2.72	EPS Q/Q	84.90%	SMA20	0.07%	Beta	0.50	Target Price	7.00
Payout	-	Debt/Eq	0.01	Sales Q/Q	-	SMA50	0.58%	Rel Volume	0.18	Prev Close	4.07
Employees	8	LT Debt/Eq	0.00	Earnings	Dec 03	SMA200	-43.25%	Avg Volume	65.36K	Price	4.05
IPO	Dec 16, 2021	Option/Short	No / Yes	EPS/Sales Surpr.	-232.40% -	Trades		Volume	11,749	Change	-0.49%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-28-23	Upgrade	H.C. Wainwright	Neutral → Buy	$8
Sep-28-23	Reiterated	Maxim Group	Buy	$7 → $10
Jan-10-22	Initiated	H.C. Wainwright	Buy	$54
Jan-10-22	Initiated	Evercore ISI	Outperform	$17
Jan-10-22	Initiated	Cantor Fitzgerald	Overweight	$52
Jan-10-22	Initiated	Berenberg	Buy	$21

Dec-08-25 08:00AM	Leading Proxy Advisory Firm ISS Recommends that Shareholders Vote the WHITE Proxy Card FOR Both of Neuphoria's Director Nominees (GlobeNewswire) +6.32%
Dec-04-25 08:00AM	Neuphoria Responds to Lynx1's Revised Indication of Interest at a Reduced Price and Premium (GlobeNewswire)
Dec-01-25 08:00AM	Neuphoria Provides Facts, Exposes False Narratives in Response to Lynx1 Fictions (GlobeNewswire)
Nov-24-25 08:00AM	Neuphoria Therapeutics Inc. Sends Letter to Stockholders (GlobeNewswire)
Nov-11-25 07:00AM	Neuphoria Announces Initiation of Strategic Review to Maximize Stockholder Value (GlobeNewswire)
04:29PM	Loading…
Oct-27-25 04:29PM	Neuphoria Therapeutics Adopts Limited-Duration Stockholder Rights Plan to Protect Integrity of Process (GlobeNewswire) -27.40%
Oct-22-25 12:53PM	Neuphoria scraps social anxiety hopeful after Phase III miss (Clinical Trials Arena) -11.34%
Oct-20-25 04:15PM	Neuphoria Therapeutics Provides Update on AFFIRM-1 Phase 3 Trial Evaluating BNC210 for the Acute Treatment of Social Anxiety Disorder (GlobeNewswire) -68.51%
Sep-29-25 04:54PM	Neuphoria Provides Fiscal Year-End 2025 Financial Results and Business Updates (GlobeNewswire)
Sep-04-25 07:00AM	Neuphoria Therapeutics Completes Target Enrollment in Phase 3 AFFIRM-1 Trial of BNC-210 in Social Anxiety Disorder (SAD) (GlobeNewswire) -8.31%
Aug-28-25 04:05PM	Neuphoria Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference (GlobeNewswire) +19.47% -7.21%
May-27-25 04:10PM	Neuphoria to Present at the American Society of Clinical Psychopharmacology (ASCP) 2025 Annual Meeting (GlobeNewswire)
May-20-25 04:22PM	Neuphoria Provides First Quarter 2025 Business Updates (GlobeNewswire) +9.86%
Apr-15-25 08:00AM	Neuphoria Provides a Review of 2024 and Highlights 2025 Plans (GlobeNewswire)
Mar-03-25 07:30AM	Neuphoria Therapeutics to Ring the Nasdaq Opening Bell on March 3rd, 2025 (GlobeNewswire) -5.19%
07:00AM	Loading…
Feb-12-25 07:00AM	Neuphoria Therapeutics Inc. to Receive $15M Milestone Payment from Merck (GlobeNewswire)
Jan-25-25 05:13PM	Why Neuphoria Therapeutics Inc. (NEUP) Surged on Friday (Insider Monkey)
Dec-24-24 05:49PM	Bionomics Strategic Shift with Neuphoria Redomiciliation (TipRanks) +118.29% -32.88%
Dec-16-24 04:05PM	Bionomics Announces Supreme Court of New South Wales Approves Bionomics' Re-Domiciliation (GlobeNewswire) -11.76%
Dec-12-24 04:05PM	Results of Scheme Meeting (GlobeNewswire) +5.29% +6.88%
Dec-09-24 08:00AM	Bionomics Publishes the Positive Results from the Phase 2 ATTUNE Study of BNC210 in Patients with Post-Traumatic Stress Disorder in NEJM Evidence (GlobeNewswire)
Dec-03-24 04:05PM	Bionomics to Present at the 2024 American College of Neuropsychopharmacology Annual Meeting (GlobeNewswire) -6.56%
Dec-02-24 05:01PM	Bionomics Reminds Shareholders to Cast their Vote for Re-Domiciliation from Australia to the United States (GlobeNewswire)
Nov-08-24 04:15PM	Bionomics Provides an Update on Re-domiciliation via Scheme of Arrangement (GlobeNewswire) +6.53% -9.12%
Nov-07-24 08:00AM	Bionomics to Present at the 2024 CNS Summit (GlobeNewswire) +36.25%
Nov-04-24 04:15PM	Bionomics Receives Milestone Payment of AUS$1M from Carina Biotech for BNC101 Partnered Legacy Oncology Program (GlobeNewswire) +157.79%
Oct-23-24 06:00AM	Bionomics to Present at the ThinkEquity Conference (GlobeNewswire)
Oct-14-24 08:00AM	Bionomics to Participate in the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLC (GlobeNewswire) -6.82%
Oct-08-24 08:50AM	Bionomics CEO believes company has significant, unrealized value (TipRanks)
Oct-07-24 08:00AM	Bionomics Issues Shareholder Letter Highlighting Recent Achievements and Strategic Vision (GlobeNewswire)
06:30AM	Loading…
Oct-01-24 06:30AM	Bionomics Limited announces intention to re-domicile to the United States (GlobeNewswire) -11.20%
Sep-03-24 06:30AM	Bionomics to Present at the H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire)
Jul-31-24 06:30AM	Bionomics Announces Successful End-of-Phase 2 Meeting with the FDA on the Development of BNC210 in Post-Traumatic Stress Disorder (GlobeNewswire) -9.78%
Jul-29-24 04:30PM	Bionomics to Provide a Corporate Update and Discuss End-of-Phase 2 Meeting Outcomes on the Development of BNC210 in PTSD on July 31, 2024 (GlobeNewswire) +24.01%
Jul-18-24 06:30AM	Bionomics Initiates AFFIRM-1, a Phase 3 Clinical Trial with BNC210 for Social Anxiety Disorder (GlobeNewswire)
May-31-24 08:00AM	Bionomics Limited Announces Private Placement of up to $70.0 Million (GlobeNewswire) -14.97%
May-20-24 06:30AM	Bionomics to Present at the 2024 American Society of Clinical Psychopharmacology Annual Meeting (GlobeNewswire)
Mar-21-24 06:00AM	Bionomics Reports Results of the Full Dataset Analysis from ATTUNE Phase 2b Trial of BNC210 in Patients with Post-Traumatic Stress Disorder (GlobeNewswire)
Feb-22-24 04:30PM	Bionomics to Present at the 2024 BIO CEO & Investor Conference (GlobeNewswire) -8.00%
Feb-05-24 03:11AM	10 Best Australian Stocks To Buy (Insider Monkey)
Feb-04-24 11:01AM	7 Strong Buy Stocks Under $20: February 2024 (InvestorPlace)
Jan-22-24 06:00AM	Bionomics Provides a Review of 2023 and of 2024 Plans (GlobeNewswire)
Jan-05-24 06:00AM	Bionomics to Present at Biotech Showcase 2024 (GlobeNewswire)
Dec-06-23 08:00AM	Bionomics Presents Detailed Data on the Validity and Reliability of the Subjective Units of Distress Scale at the 2023 American College of Neuropsychopharmacology Annual Meeting (GlobeNewswire) +5.08%
Oct-30-23 02:02PM	12 Best Stocks For Day Trading (Insider Monkey)
Oct-16-23 08:00AM	Bionomics Announces Successful End-of-Phase 2 Meeting with the FDA and Solidifies Plans to Initiate the Registrational Program for BNC210 in Social Anxiety Disorder (GlobeNewswire) +14.18%
Sep-29-23 08:51AM	Bionomics (BNOX) Meets Goals in PTSD Study, Stock Rallies 244% (Zacks) -19.88%
12:13AM	Bionomics Announces Positive Topline Results from the Phase 2b ATTUNE Clinical Trial of BNC210 in Patients with Post-Traumatic Stress Disorder (PTSD) (PR Newswire)
Sep-28-23 08:03AM	Why Is Bionomics (BNOX) Stock Up 347% Today? (InvestorPlace) +242.13%
07:09AM	Bionomics' midphase PTSD trial hits primary endpoint, briefly tripling its battered share price (FierceBiotech.com)
06:00AM	Bionomics Announces Positive Topline Results from the Phase 2b ATTUNE Clinical Trial of BNC210 in Patients with Post-Traumatic Stress Disorder (PTSD) (GlobeNewswire)
Sep-14-23 06:00AM	Bionomics Announces Update on the 7 Nicotinic Acetylcholine Receptor (nAChR) Positive Allosteric Modulator (PAM) Collaboration with MSD (GlobeNewswire) -25.14%
Aug-24-23 11:50AM	Bionomics (BNOX) Up on Positive Updates on PTSD & SAD Candidate (Zacks) +7.91%
Aug-23-23 06:00AM	Bionomics Completes Last Patient Last Visit in the Phase 2b ATTUNE Study for Post-Traumatic Stress Disorder (PTSD) and Confirms Expected 2023 Milestones with its Lead Asset BNC210 (GlobeNewswire) +15.83%
Jul-31-23 06:00AM	Quarterly Activities and Cashflow Report (GlobeNewswire) -14.14%
Jul-25-23 06:00AM	Bionomics Announces Intention to Delist from the Australian Securities Exchange (ASX) (GlobeNewswire) -15.93%
Jul-15-23 08:27PM	Is Bionomics (ASX:BNO) In A Good Position To Deliver On Growth Plans? (Simply Wall St.)
Jul-03-23 06:00AM	Bionomics Announces Key Leadership Updates to Drive U.S.-Focused Transformation and Next Stage of Strategic Growth (GlobeNewswire) +5.95%
Jun-15-23 08:00AM	Bionomics to Present at Upcoming June Investor Conferences (GlobeNewswire)
May-30-23 06:00AM	Bionomics Announces Upcoming Poster Presentation at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting (GlobeNewswire) -5.62%
Apr-28-23 06:00AM	Quarterly Activities and Cashflow Report (GlobeNewswire)
Apr-27-23 06:00AM	Bionomics Announces the Completion of Enrollment in Phase 2b ATTUNE Clinical Trial of BNC210 in Patients with Post-Traumatic Stress Disorder (PTSD) (GlobeNewswire)
Mar-09-23 10:54AM	Bionomics Reveals Detailed Data From Its Flunked Anxiety Trial, Shows Reductions In Anxiety Across Multiple Phases (Benzinga) -26.24%
Mar-08-23 07:00PM	Bionomics Reports Promising Full Results Analysis from PREVAIL Phase 2 Study of BNC210 Social Anxiety Disorder (SAD) (GlobeNewswire) +7.39%
Mar-03-23 09:55AM	Bears are Losing Control Over Bionomics Limited Unsponsored ADR (BNOX), Here's Why It's a 'Buy' Now (Zacks)
Feb-24-23 03:05PM	Bionomics First Half 2023 Earnings: AU$0.012 loss per share (vs AU$0.013 loss in 1H 2022) (Simply Wall St.) +19.03%
Feb-23-23 06:00AM	Bionomics Half-Year Report (GlobeNewswire) +9.47%
Feb-05-23 07:02PM	Will Bionomics (ASX:BNO) Spend Its Cash Wisely? (Simply Wall St.)
Jan-30-23 06:23PM	Quarterly Activities and Cashflow Report (GlobeNewswire) -6.20%
Dec-19-22 03:29PM	All Focus Shifts To Bionomics' PTSD Study After Anxiety Trial Disappoints (Benzinga) -13.38%
09:30AM	Bionomics' Social Anxiety Disorder Study Fails To Meet Primary Endpoint (Benzinga)
Dec-18-22 07:34PM	Bionomics Reports Topline Results in PREVAIL Phase 2 Study of BNC210 in Social Anxiety Disorder (GlobeNewswire)
Dec-15-22 06:35PM	Bionomics appoints Spyridon Spyros Papapetropoulos as President and Chief Executive Officer (GlobeNewswire)
Dec-02-22 06:00AM	Bionomics Announces Accepted Abstract and Upcoming Poster Presentations at the American College of Neuropsychopharmacology (ACNP) 2022 Annual Meeting (GlobeNewswire)
Nov-21-22 06:13PM	Bionomics Limited Announces Closing of US$5 Million Underwritten Offering of American Depositary Shares in the United States (GlobeNewswire)
Nov-16-22 06:36PM	Bionomics Limited Announces Pricing of Underwritten Offering of American Depositary Shares in the United States (GlobeNewswire) -17.41%
Nov-02-22 06:00AM	Bionomics Limited to Participate in Upcoming November Investor Conferences (GlobeNewswire)
Oct-25-22 06:00AM	Quarterly Activities Report for September 2022 (GlobeNewswire)
Oct-18-22 06:00AM	Bionomics Receives R&D Tax Incentive Refund for FY2022 of A$4.6 million (GlobeNewswire)
Oct-07-22 04:39PM	Bionomics (ASX:BNO) adds AU$20m to market cap in the past 7 days, though investors from five years ago are still down 84% (Simply Wall St.)
Oct-04-22 06:00AM	Bionomics Limited to Participate in the Cantor Neurology & Psychiatry Conference (GlobeNewswire)
Sep-21-22 06:00AM	Bionomics to Host KOL Webinar on BNC210 and Social Anxiety Disorder (GlobeNewswire)
Sep-15-22 09:55AM	Can Bionomics Limited Unsponsored ADR (BNOX) Climb 329% to Reach the Level Wall Street Analysts Expect? (Zacks)
Aug-31-22 06:00AM	Bionomics to Participate in Upcoming September Investor Conferences (GlobeNewswire)
Aug-30-22 09:55AM	Does Bionomics Limited Unsponsored ADR (BNOX) Have the Potential to Rally 329% as Wall Street Analysts Expect? (Zacks)
Aug-27-22 06:26PM	We're Keeping An Eye On Bionomics' (ASX:BNO) Cash Burn Rate (Simply Wall St.)
Aug-25-22 06:00AM	Bionomics reports Full Year Financial Results (GlobeNewswire) +7.42%
Aug-08-22 06:00AM	Bionomics Receives R&D Tax Incentive Refund for FY2021 of A$2.1M (GlobeNewswire)
Jul-29-22 06:00AM	Quarterly Activities Report for June 2022 (GlobeNewswire)
Jul-08-22 06:00AM	Bionomics to Participate in William Blairs Biotech Focus Conference 2022 (GlobeNewswire) +8.82%
Jun-27-22 06:00AM	Bionomics Limited to Participate in the H.C. Wainwright Mental Health Conference (GlobeNewswire)
Jun-24-22 07:44AM	Fewer Investors Than Expected Jumping On Maxim Power Corp. (TSE:MXG) (Simply Wall St.)
Jun-13-22 04:30PM	Bionomics Investor Webinar (GlobeNewswire) -14.02% +5.62%
May-16-22 06:00AM	Bionomics Limited to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-10-22 08:00AM	Novamind to Host Bionomics PREVAIL Trial for Acute Treatment of Social Anxiety Disorder (ACCESSWIRE)
Feb-23-22 09:00PM	Bionomics' Half-Year Report (GlobeNewswire)
Jan-14-22 07:06AM	Bionomics Limited (Nasdaq: BNOX, ASX: BNO) to Ring the Nasdaq Stock Market Closing Bell on Friday January 14, 2022 (PR Newswire)
Jan-12-22 06:00AM	Bionomics Limited participated in the H.C Wainwright BioConnect Conference (PR Newswire)
Jan-05-22 05:58PM	Bionomics Limited Announces Full Exercise of Underwriters' Option to Purchase Additional ADSs in the United States (PR Newswire)
Jan-03-22 06:00AM	Bionomics Initiates Phase 2 PREVAIL Study of BNC210 for the Acute Treatment of Social Anxiety Disorder (PR Newswire)

Neuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Lynx1 Capital Management LP	10% Owner	Oct 21 '25	Buy	5.14	639,110	3,283,108	875,328	Oct 23 07:49 PM

Open in Screener

PASG

Passage Bio Inc

Feb 13 • 04:00PM ET

8.81

+0.08 0.92 %

Healthcare • Biotechnology • USA • NASD

Peers: CRSP ADPT NTLA QURE EDIT CLLS BLUE REPL MGTX

| Held by: VTI VXF DCOR DFAC

Index	-	P/E	-	EPS (ttm)	-14.46	Insider Own	5.21%	Shs Outstand	3.18M	Perf Week	-7.36%
Market Cap	27.49M	Forward P/E	-	EPS next Y	-6.19	Insider Trans	18.93%	Shs Float	2.96M	Perf Month	-41.89%
Enterprise Value	-0.94M	PEG	-	EPS next Q	-2.57	Inst Own	47.63%	Short Float	0.38%	Perf Quarter	-6.08%
Income	-45.26M	P/S	-	EPS this Y	54.07%	Inst Trans	0.54%	Short Ratio	0.18	Perf Half Y	16.07%
Sales	0.00M	P/B	0.90	EPS next Y	37.03%	ROA	-48.69%	Short Interest	0.01M	Perf YTD	-25.34%
Book/sh	9.79	P/C	0.52	EPS next 5Y	50.89%	ROE	-87.18%	52W High	20.00 -55.95%	Perf Year	-15.81%
Cash/sh	16.91	P/FCF	-	EPS past 3/5Y	32.43% -1.48%	ROIC	-87.19%	52W Low	5.12 71.94%	Perf 3Y	-65.85%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	13.39% 13.59%	Perf 5Y	-97.92%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	38.42%	Oper. Margin	-	ATR (14)	1.48	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	2.51	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	37.01	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	2.51	EPS Q/Q	61.07%	SMA20	-19.41%	Beta	1.76	Target Price	32.75
Payout	-	Debt/Eq	0.78	Sales Q/Q	-	SMA50	-24.54%	Rel Volume	0.20	Prev Close	8.73
Employees	60	LT Debt/Eq	0.67	Earnings	Nov 10 AMC	SMA200	4.05%	Avg Volume	62.05K	Price	8.81
IPO	Feb 28, 2020	Option/Short	No / Yes	EPS/Sales Surpr.	11.51% -	Trades		Volume	12,209	Change	0.92%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-10-26	Resumed	Chardan Capital Markets	Buy	$21
Nov-29-24	Resumed	Wedbush	Outperform	$3 → $4
Sep-03-24	Initiated	Rodman & Renshaw	Buy	$7
Mar-08-22	Downgrade	JP Morgan	Overweight → Neutral
Jan-19-22	Downgrade	Goldman	Buy → Neutral	$29 → $6
Jul-01-21	Initiated	Raymond James	Outperform	$29
Jun-15-21	Initiated	BTIG Research	Buy	$25
Mar-04-21	Upgrade	Goldman	Neutral → Buy	$28 → $30
Feb-04-21	Initiated	Guggenheim	Buy	$25
Jan-25-21	Initiated	Wedbush	Outperform	$26
Jan-04-21	Upgrade	JP Morgan	Neutral → Overweight	$25 → $35
Dec-11-20	Initiated	Citigroup	Neutral	$28
Aug-14-20	Downgrade	JP Morgan	Overweight → Neutral	$25
Jun-25-20	Downgrade	Goldman	Buy → Neutral	$28
Mar-25-20	Initiated	Chardan Capital Markets	Buy	$30
Mar-24-20	Initiated	JP Morgan	Overweight	$25
Mar-24-20	Initiated	Goldman	Buy	$27
Mar-24-20	Initiated	Cowen	Outperform

Show Previous Ratings

Nov-10-25 04:15PM	Passage Bio Reports Third Quarter 2025 Financial Results and Provides Recent Business Highlights (GlobeNewswire) +6.68% +14.84%
Nov-05-25 07:00AM	Passage Bio to Present at Guggenheim Securities 2nd Annual Healthcare Innovation Conference (GlobeNewswire)
Oct-14-25 07:00AM	Passage Bio to Participate in Chardan's 9th Annual Genetic Medicines Conference (GlobeNewswire)
Sep-01-25 09:55AM	Wall Street Analysts Think Passage Bio (PASG) Could Surge 731%: Read This Before Placing a Bet (Zacks)
Aug-28-25 07:00AM	Passage Bio to Participate in H.C. Wainwright 27th Annual Global Investment Conference (GlobeNewswire)
09:55AM	Loading…
Aug-15-25 09:55AM	Wall Street Analysts Believe Passage Bio (PASG) Could Rally 1415.15%: Here's is How to Trade (Zacks) -8.43%
09:25AM	Passage Bio price target lowered to $67 from $260 at Canaccord (TipRanks)
Aug-12-25 07:00AM	Passage Bio Reports Second Quarter 2025 Financial Results and Provides Recent Business Highlights (GlobeNewswire)
Jul-10-25 07:00AM	Passage Bio Announces 1-for-20 Reverse Stock Split (GlobeNewswire) -9.86%
Jun-23-25 07:00AM	Passage Bio Reports Updated Interim Data from upliFT-D Study and Provides Program Update (GlobeNewswire) -14.37%
May-13-25 07:00AM	Passage Bio Reports First Quarter 2025 Financial Results and Provides Recent Business Highlights (GlobeNewswire)
Mar-07-25 12:00PM	Passage Bio (PASG) Upgraded to Buy: Here's What You Should Know (Zacks)
Mar-04-25 07:00AM	Passage Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Recent Business Highlights (GlobeNewswire) -11.37%
Feb-26-25 07:00AM	Passage Bio to Participate in Upcoming Investor Conferences (GlobeNewswire)
Jan-10-25 07:00AM	Passage Bio Announces Interim Data from upliFT-D Study in FTD-GRN and Provides Business Updates (GlobeNewswire)
06:55AM	Loading…
Nov-30-24 06:55AM	Passage Bio assumed with an Outperform at Wedbush (TipRanks)
Nov-14-24 07:29AM	Passage Bio Achieves Milestones in Gene Therapy Trials (TipRanks)
Nov-13-24 07:00AM	Passage Bio Reports Third Quarter 2024 Financial Results and Provides Recent Business Highlights (GlobeNewswire) -12.87%
Nov-06-24 07:00AM	Passage Bio to Present at Guggenheim Securities Healthcare Innovation Conference (GlobeNewswire)
Oct-24-24 07:00AM	Passage Bio Presents Preclinical and Interim Clinical Data for PBFT02 in FTD-GRN at the European Society of Gene & Cell Therapy (ESGCT) 31st Annual Conference (GlobeNewswire) +11.40%
Sep-23-24 09:36PM	Orbimed Advisors LLC Adjusts Stake in Passage Bio Inc (GuruFocus.com) -5.11%
07:00AM	Passage Bio to Present at Chardan's 8th Annual Genetic Medicines Conference (GlobeNewswire)
Sep-19-24 01:25AM	Orbimed Advisors LLC Reduces Stake in Passage Bio Inc (GuruFocus.com)
Sep-16-24 07:00AM	Passage Bio to Present Positive Interim Data from Cohort 1 Patients with FTD-GRN in upliFT-D Study at 14th International Conference on Frontotemporal Dementias (ISFTD2024) (GlobeNewswire) -9.45%
Sep-10-24 07:52AM	Passage Bio Welcomes Tom Kassberg to Board of Directors (GlobeNewswire) +6.06%
Aug-30-24 07:00AM	Passage Bio to Present at H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire) -5.96%
Aug-08-24 07:00AM	Passage Bio Reports Second Quarter 2024 Financial Results and Provides Recent Business Highlights (GlobeNewswire) -5.22%
Aug-06-24 07:00AM	Passage Bio to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-01-24 12:30PM	Jim Wilson, prominent gene therapy researcher, to depart UPenn (BioPharma Dive) +6.63%
07:00AM	Passage Bio Out-licenses Three Pediatric Gene Therapy Programs to GEMMA Biotherapeutics and Enters New Research Collaboration (GlobeNewswire)
07:13AM	Loading…
Jul-25-24 07:13AM	Passage Bio targets FDA to greenlight ALS gene therapy trial (Clinical Trials Arena) +6.23%
Jul-16-24 07:43AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday (InvestorPlace)
07:00AM	Passage Bio Announces Positive Feedback from FDA on Expansion of upliFT-D Trial of PBFT02 to Include FTD-C9orf72 Patients (GlobeNewswire)
Jun-18-24 09:35AM	Passage Bio (PASG) Loses -22.9% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks) -5.45%
Jun-05-24 07:30AM	Passage Bio to Present at Goldman Sachs 45th Annual Global Healthcare Conference (GlobeNewswire)
May-21-24 08:00AM	Passage Bio Announces Recipient of Third Annual Tachi Yamada Scholarship Award (GlobeNewswire)
May-16-24 12:00PM	All You Need to Know About Passage Bio (PASG) Rating Upgrade to Buy (Zacks)
May-14-24 01:54PM	PASG Stock Earnings: Passage Bio Beats EPS for Q1 2024 (InvestorPlace) -10.47%
07:00AM	Passage Bio Reports First Quarter 2024 Financial Results and Provides Recent Business Highlights (GlobeNewswire)
Apr-22-24 07:00AM	Passage Bio to Present at Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit (GlobeNewswire)
Mar-07-24 12:00PM	Passage Bio, Inc. (PASG) Is Up 24.26% in One Week: What You Should Know (Zacks) -6.43%
Mar-06-24 01:52PM	PASG Stock Earnings: Passage Bio Beats EPS for Q4 2023 (InvestorPlace)
Mar-05-24 07:00AM	Passage Bio Seeks Pennsylvania College Student Candidates for Third Annual Tachi Yamada Scholarship Program (GlobeNewswire)
Mar-04-24 07:00AM	Passage Bio Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Recent Business Highlights (GlobeNewswire)
Feb-27-24 07:00AM	Passage Bio to Participate in Upcoming Investor Conferences (GlobeNewswire) +6.12%
Feb-01-24 07:09PM	7 Analyst-Backed Stocks With Promising 10-Bagger Potential (InvestorPlace) +5.13%
Jan-31-24 07:30AM	Passage Bio to Present at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference (GlobeNewswire)
Dec-25-23 10:14PM	7 Nano-Cap Stocks That Pack a Serious Punch for Their Weight (InvestorPlace)
Dec-20-23 07:00AM	Passage Bio Announces Promising Initial Data From Phase 1/2 Clinical Trial of PBFT02 in FTD-GRN and Updated Strategic Priorities (GlobeNewswire) +7.35%
Nov-17-23 04:30PM	Passage Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire)
Nov-13-23 07:00AM	Passage Bio Reports Third Quarter 2023 Financial Results and Provides Recent Business Highlights (GlobeNewswire)
Oct-30-23 07:00AM	Passage Bio to Present at Guggenheim's 5th Annual Inflammation, Neurology & Immunology Conference (GlobeNewswire) +6.91%
Oct-20-23 04:30PM	Passage Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-25-23 07:00AM	Passage Bio to Present at Chardans 7th Annual Genetic Medicines Conference (GlobeNewswire)
Aug-11-23 10:04AM	Lab Notes: Almac Group starts work on $65M Montco expansion expected to create 355 jobs (American City Business Journals)
Aug-07-23 07:15AM	Passage Bio Reports Second Quarter 2023 Financial Results and Provides Recent Business Highlights (GlobeNewswire) -5.11%
07:00AM	Passage Bio Announces Promising Interim Clinical Data from First Eight Patients with GM1 Gangliosidosis in Imagine-1 Study (GlobeNewswire)
Aug-01-23 07:00AM	Passage Bio to Participate in Upcoming Investor Conferences (GlobeNewswire)
Jul-31-23 07:00AM	Passage Bio Welcomes Dolan Sondhi, Ph.D. to Board Of Directors (GlobeNewswire)
Jul-24-23 12:37PM	Passage Bio reduces staff by 26% in latest round of job cuts (American City Business Journals) -5.31%
Jul-06-23 11:17AM	12 Best Nano Cap Stocks To Buy Now (Insider Monkey)
Jun-05-23 07:00AM	Passage Bio to Present at Goldman Sachs 44th Annual Global Healthcare Conference (GlobeNewswire)
May-11-23 07:00AM	Passage Bio Reports First Quarter 2023 Financial Results and Provides Recent Business Highlights (GlobeNewswire)
May-04-23 07:00AM	Passage Bio Announces Recipient of Second Annual Tachi Yamada Scholarship Award (GlobeNewswire) +5.91%
Apr-21-23 04:01PM	Passage Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-17-23 07:00AM	Passage Bio to Present at Chardans 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit (GlobeNewswire)
Mar-29-23 09:02AM	Is Passage Bio (NASDAQ:PASG) In A Good Position To Invest In Growth? (Simply Wall St.)
Mar-27-23 07:00AM	Passage Bio to Present at Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Days (GlobeNewswire)
Mar-08-23 07:14AM	Passage Bio, Inc. (NASDAQ:PASG) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-07-23 12:42AM	Q4 2022 Passage Bio Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-06-23 07:00AM	Passage Bio Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Recent Business Highlights (GlobeNewswire)
Mar-01-23 07:00AM	Passage Bio Seeks Pennsylvania College Student Candidates for Second Annual Tachi Yamada Scholarship Program (GlobeNewswire)
Feb-28-23 07:00AM	Passage Bio to Present at Cowen 43rd Annual Health Care Conference (GlobeNewswire)
Feb-27-23 07:00AM	Passage Bio to Report Fourth Quarter and Full-Year 2022 Financial Results on March 6, 2023 (GlobeNewswire) +7.69%
Feb-24-23 07:00AM	Passage Bio Presents Additional Interim Data from Imagine-1 Study for GM1 Gangliosidosis at 19th Annual WORLDSymposium 2023 (GlobeNewswire) -7.87%
Feb-20-23 05:59PM	'We've turned the page': CEO says Passage Bio is building momentum after turbulent 2022 (American City Business Journals)
Feb-15-23 07:00AM	Passage Bio to Present Updated Interim Data from Imagine-1 Study for GM1 Gangliosidosis at 19th Annual WORLDSymposium 2023 (GlobeNewswire)
Jan-20-23 04:01PM	Passage Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-07-23 07:39AM	After losing 67% in the past year, Passage Bio, Inc. (NASDAQ:PASG) institutional owners must be relieved by the recent gain (Simply Wall St.)
Dec-14-22 12:13PM	Passage Bio Stock Jumps After Gene Therapy Study In Lysosomal Storage Disorder (Benzinga) +9.65%
07:00AM	Passage Bio Announces Positive Interim Clinical Data from First Six Patients with GM1 Gangliosidosis in Imagine-1 Study (GlobeNewswire)
Nov-21-22 05:24AM	Estimating The Fair Value Of Passage Bio, Inc. (NASDAQ:PASG) (Simply Wall St.)
Nov-10-22 07:00AM	Passage Bio Reports Third Quarter 2022 Financial Results and Provides Business Updates (GlobeNewswire) +10.83%
Nov-08-22 07:00AM	Passage Bio to Present at Guggenheim 4th Annual Immunology & Neurology Day (GlobeNewswire)
Nov-03-22 07:30AM	Passage Bio to Report Third Quarter 2022 Financial Results on November 10, 2022 (GlobeNewswire)
Oct-14-22 04:01PM	Passage Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.88%
Oct-11-22 12:25PM	Here's Why Passage Bio (NASDAQ:PASG) Must Use Its Cash Wisely (Simply Wall St.)
Oct-10-22 07:00AM	Passage Bio Announces Appointment of William Chou, M.D. as Chief Executive Officer (GlobeNewswire)
Sep-26-22 07:00AM	Passage Bio to Present at Chardans 6th Annual Genetic Medicines Conference (GlobeNewswire)
Aug-19-22 04:01PM	Passage Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire)
Aug-11-22 07:00AM	Passage Bio Doses First Patient in Global Clinical Trial of PBFT02 Gene Therapy for Frontotemporal Dementia with Granulin Mutations (GlobeNewswire)
Aug-05-22 07:00AM	Passage Bio to Present at 2022 Wedbush PacGrow Healthcare Virtual Conference (GlobeNewswire)
Aug-04-22 07:00AM	Passage Bio Reports Second Quarter 2022 Financial Results and Provides Recent Business Highlights (GlobeNewswire)
Jul-28-22 07:30AM	Passage Bio to Report Second Quarter 2022 Financial Results on August 4, 2022 (GlobeNewswire) -7.98%
Jul-21-22 04:01PM	Passage Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-12-22 08:19AM	What Kind Of Investors Own Most Of Passage Bio, Inc. (NASDAQ:PASG)? (Simply Wall St.)
Jul-06-22 07:00AM	Passage Bio Appoints Michael Kamarck, Ph.D. to Board of Directors (GlobeNewswire)
Jun-09-22 07:30AM	Passage Bio to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference (GlobeNewswire)
Jun-08-22 07:30AM	Passage Bio Receives FDA Clearance of IND Application for PBML04 for Treatment of Metachromatic Leukodystrophy (GlobeNewswire)
Jun-01-22 10:19AM	Passage Bio and CEO Bruce Goldsmith part ways (American City Business Journals)

Passage Bio, Inc. operates as a genetic medicines company. It focuses on developing transformative therapies for rare, monogenic central nervous system disorders with limited or no approved treatment options. The company assembles a portfolio of genetic medicine products, which includes PBGM01 for the treatment of GM1, PBFT02 for the treatment of FTD and PBKR03 for the treatment of Krabbe disease. Passage Bio was founded by Stephen P. Squinto, Tadataka Yamada, David A. Socks, Aditya Kohli, and James M. Wilson in July 2017 and is headquartered in Philadelphia, PA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Chou William	PRESIDENT AND CEO	Jan 08 '26	Sale	18.44	4,076	75,159	6,524	Jan 12 04:03 PM
Borthwick Kathleen	CFO	Jan 08 '26	Sale	18.44	2,062	38,022	5,402	Jan 12 04:03 PM
Chou William	Officer	Jan 09 '26	Proposed Sale	18.43	4,076	75,120		Jan 09 04:03 PM
Lynx1 Capital Management LP	10% Owner	Sep 12 '25	Buy	6.99	19,783	138,299	611,804	Sep 15 08:05 PM
Lynx1 Capital Management LP	10% Owner	Sep 15 '25	Buy	6.99	11,900	83,175	623,704	Sep 15 08:05 PM
Lynx1 Capital Management LP	10% Owner	Sep 11 '25	Buy	6.96	325	2,261	592,021	Sep 15 08:05 PM
Lynx1 Capital Management LP	10% Owner	Jul 24 '25	Buy	5.71	66,423	379,455	591,696	Jul 24 06:12 PM
Lynx1 Capital Management LP	10% Owner	Jul 23 '25	Buy	5.74	49,302	283,033	525,273	Jul 24 06:12 PM
Lynx1 Capital Management LP	10% Owner	Jul 22 '25	Buy	5.44	13,123	71,338	475,971	Jul 24 06:12 PM
OrbiMed Private Investments VI	Stockholder	Jul 21 '25	Proposed Sale	5.56	132,645	737,506		Jul 21 05:33 PM
OrbiMed Private Investments VI	Stockholder	Jul 15 '25	Proposed Sale	6.79	53,293	361,859		Jul 15 08:17 PM
OrbiMed Private Investments VI	Stockholder	Jul 07 '25	Proposed Sale	0.43	259,000	112,147		Jul 07 06:02 PM
ORBIMED ADVISORS LLC	10% Owner	Jun 24 '25	Sale	0.35	231,600	81,060	6,418,400	Jun 26 05:10 PM
ORBIMED ADVISORS LLC	10% Owner	Jun 26 '25	Sale	0.33	213,257	70,375	6,066,343	Jun 26 05:10 PM
ORBIMED ADVISORS LLC	10% Owner	Jun 25 '25	Sale	0.33	138,800	45,804	6,279,600	Jun 26 05:10 PM
OrbiMed Private Investments VI	Stockholder	Jun 24 '25	Proposed Sale	0.35	1,076,120	378,364		Jun 24 06:48 PM
ORBIMED ADVISORS LLC	10% Owner	Apr 23 '25	Sale	0.34	89,328	30,372	6,718,195	Apr 24 05:38 PM
ORBIMED ADVISORS LLC	10% Owner	Apr 22 '25	Sale	0.34	78,049	26,537	6,807,523	Apr 24 05:38 PM
ORBIMED ADVISORS LLC	10% Owner	Apr 24 '25	Sale	0.32	68,195	21,822	6,650,000	Apr 24 05:38 PM
ORBIMED ADVISORS LLC	10% Owner	Apr 17 '25	Sale	0.33	77,090	25,440	6,885,572	Apr 17 06:10 PM
ORBIMED ADVISORS LLC	10% Owner	Apr 16 '25	Sale	0.33	61,638	20,341	6,962,662	Apr 17 06:10 PM
ORBIMED ADVISORS LLC	10% Owner	Apr 15 '25	Sale	0.38	10,326	3,924	7,024,300	Apr 17 06:10 PM
OrbiMed Private Investments VI	Stockholder	Apr 15 '25	Proposed Sale	0.38	787,179	301,490		Apr 15 05:40 PM

TCRX

Tscan Therapeutics Inc

CGEM

Cullinan Therapeutics Inc

NEUP

Neuphoria Therapeutics Inc

PASG

Passage Bio Inc

Upgrade your FINVIZ experience